Home

Investors & News

Corporate Profile

Tengion’s first clinical program is the Neo-Kidney Augment™, which is intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease (CKD). According to the United States Renal Data System, there are approximately 26 million adults in the U.S. who have chronic kidney disease (CKD), and there are 100,000 new patients who start on dialysis each year. $39 billion in direct U.S. costs each year are attributable to patients with end-stage renal disease, which is associated with an approximate 20% mortality rate per year and an average life expectancy of a patient initiating dialysis of approximately four years. The Neo-Ki... More >>

Recent News More >>
Upcoming Events More >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Investor Resources
TNGN(Common Stock)
ExchangeOTC BB (US Dollar)
Price$0.06
Change (%)0.00 (0.00%)
Volume19,613
Data as of 09/18/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
August 13, 2014
Tengion Provides Clinical Update and Reports Second Quarter 2014 Financial Results
WINSTON-SALEM, N.C., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported key clinical data along with financial and operating results for the quarter ended June 30, 2014. "Today, we are pleased to announce encouraging six-month interim data for the first five patients implanted in the Phase 1 clinical trial of our Neo-Kidney Augment (NKA) cellular therapy being conducted in Sweden. We believe these early trends support the promising... 
May 15, 2014
Tengion Reports First Quarter 2014 Financial Results
WINSTON-SALEM, N.C., May 15, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported its financial results for the first quarter ended March 31, 2014. "We are actively continuing patient enrollment in our ongoing Phase 1 clinical trials for the Neo-Kidney Augment in both Sweden and in the United States. We are also working with key opinion leaders to determine future development plans for the Neo-Urinary Conduit," commented John L. Miclot, Presi...